19
Participants
Start Date
April 30, 2014
Primary Completion Date
February 28, 2019
Study Completion Date
January 31, 2021
Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
University of Michigan Health System Department of Neurosurgery, Ann Arbor
Phase One Foundation
OTHER
University of Michigan Rogel Cancer Center
OTHER